Jamshedpur: Meherbai Tata Memorial Hospital to get 4-bed ICU on December 22

"We would also start Lutetium therapy at MTMH by this year-end for prostate cancer patients who have not responded to conventional treatment. This would be the first such facility in the state of Jharkhand," said Dr Mitra.

Published On 2022-11-10 04:30 GMT   |   Update On 2022-11-21 11:41 GMT

Jamshedpur: Expanding its wings, Meherbai Tata Memorial Hospital (MTMH) will launch a new 4-bed Intensive Care Unit (ICU) on December 22, announcing that new facilities will also be added to cater to the needs of cancer patients. The hospital will start Lutetium therapy — the first kind ever in the state. Lutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic...

Login or Register to read the full article

Jamshedpur: Expanding its wings, Meherbai Tata Memorial Hospital (MTMH) will launch a new 4-bed Intensive Care Unit (ICU) on December 22, announcing that new facilities will also be added to cater to the needs of cancer patients.

The hospital will start Lutetium therapy — the first kind ever in the state. Lutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic medicine for advanced metastatic prostate cancer. It's a type of radiation that specifically targets a molecule on the surface of prostate cancer cells called PSMA.

A new MRI machine will be installed at the Tata Main Hospital campus for the convenience of the patients. To protect blood cancer patients from any infection, the hospital has recently established three specialised cabins for their safety. 

Also read- Tata Memorial Centre, Vedanta BALCO Medical Centre Collaborate For Cancer Care

A state-of-the-art TrueBeam radiotherapy machine has been installed at MTMH which is a medical linear accelerator developed by Varian Medical Systems. It provides image-guided stereotactic radiosurgery and radiotherapy with high precision to treat tumours and lesions in various parts of the body, including the lungs, breasts, head, and neck.

MTMH director and nuclear medicine department head Dr Sujata Mitra told The Telegraph, "At present, sick patients from Tata Main Hospital are transported to MTMH campus for MRI scan. With the installation of a second MRI, patients will save time and their transportation will be safer."

"We would also start Lutetium therapy at MTMH by this year-end for prostate cancer patients who have not responded to conventional treatment. This would be the first such facility in the state of Jharkhand," said Dr Mitra.

"This year we would be holding a cancer awareness rally organised together with the Inner Wheel Club of Jamshedpur on November 9 to educate the public. Schoolchildren, doctors, nurses and prominent members of the society will be participating in this rally which will begin from the Bistupur Post Office roundabout and culminate at Gopal Maidan," said Dr Mitra.

"We will be observing Children's Day with children fighting cancer at Kudy Mahanty Auditorium in Jamshedpur on November 14 where MTMH would like to recognize these brave hearts as well as thank sponsors who have donated towards their treatment," informed Dr Mitra.

Named after Lady Meherbai Tata, wife of Sir Dorabji Tata who was a pioneering champion of social change and women's rights more than a century ago, the Meherbai Tata Memorial Hospital (MTMH), Jamshedpur, has been serving cancer patients from Jharkhand and neighbouring states since 1975.

The hospital is run and managed by Tata Steel. At present, the hospital caters to 25,000 OPD patients annually and 9,500 admission patients, of which 3,000 are new. The number of patients has been increasing by 7% year on year.

Also read- Odisha, Tata Memorial Centre Signs MoU For Rs 650 Crore Cancer Hospital

Tags:    
Article Source : With Inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News